Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Highlights

Green light from Europe for the Genopole-coordinated project GEN.ERA


The Genopole-coordinated European project GEN.ERA* has been selected by the European Commission. GEN.ERA seeks to harness inter-cluster cooperation for the internationalization of genomics companies beyond European borders.
Genopole - European projects Genopole - European projects

The project represents an important step for Genopole in its international goals. It also lays a foundation for European partnerships in genomics.

European Strategic Cluster Partnerships-Going International LogoGEN.ERA is part of the Cluster Go International call of the European program COSME.
It unites Genopole with Italian (Distretto Tecnologico Campania Bioscience), Estonian (Tartu BT Park), and Finnish (Turku Science Park Ltd) clusters, and the East-Netherlands Development Agency.

 

Goal:


GEN.ERA’s objective is to construct within a two-year timeline a European inter-cluster strategy to identify promising markets and ease access to them for businesses positioned in the genomics value chain.

By sharing their experiences and constructing a shared strategy for internationalization, the five partners will be able to approach the global market as a single pan-European cluster and thus better support the development of their start-ups and SMEs beyond Europe.

This ambitious project will begin in early May and Genopole’s companies will be invited to contribute to its realization.

By obtaining the European GEN.ERA project, Genopole confirms the momentum of its ecosystem and its determination to grow in international influence. “The competitiveness of our businesses is a major issue,” underlines Acting Director General of Genopole Anne Jouvenceau. “Pertinent accompaniment aimed at future-looking markets is a key to success.

* Project GEN.ERA : diGital gENomic alliance to Explore new maRket for Acceleration.

Article posted on 14 February 2020

Share
Highlights

The latest news


AB Science L. Gros

Multiple sclerosis and COVID-19: promising results from AB Science

AB Science has been announcing a series of positive results concerning the efficacy of its product, masitinib, in such pathologies as multiple sclerosis, severe asthma resistant to oral steroids, COVID-19 and amyotrophic lateral sclerosis.

Discover
Placton - Tara Oceans

Bioinformatics and Tara Oceans

A team from the Genomics Metabolics Laboratory (Genoscope – CEA/CNRS/University of Évry) has developed a bioinformatics method for environmental genomics analyses able to identify species and associations of species.

Discover
Globules rouges - Avancées scientifiques

CRISPR-Cas9 for blood and metabolic diseases – Integrare

In an article published in Nature Communications, an Integrare team headed by Dr. Mario Amendola has described an innovative genome editing strategy aimed at modifying hematopoietic stem cells.

Discover
Généthon - Genopole's Laboratory

Treating more patients with gene therapies – Généthon

A Genethon team has successfully inhibited immune response to adeno-associated virus vectors, and in so doing, opened potential paths for treating more patients with gene therapies.

Discover
COVID-19 Disease Map

A single interactive map for all that is known on COVID-19

The objective for this latter is to build a sole referential comprising the totality of scientific knowledge on SARS-CoV-2/human-host interactions and thus contribute to the identification of therapeutic possibilities.

Discover
cellular membrane

Mapping membrane nanotubes – Lambe

A team from the Genopole-accredited Laboratory for Analysis and Modeling in Biology and the Environment (Lambe) has developed an experimental technique to study cell membrane nanotubes. These largely unknown structures play an essential role in cellular biomolecule transport.

Discover
Laboratory

Toward the industrialization of gene therapies -Polytheragene

Polytheragene is developing a polymer that will improve upon the current market standards for the production of viral particles for therapeutics. The polymer will be used by Genethon and Yposkesi to enhance the bioproduction of gene therapy vectors.

Discover
Jean Weissenbach

Jean Weissenbach: a portrait

Jean Weissenbach, a pioneer in France for the exploration of the human genome and a scientific icon at Genopole, talks about his career in an interview published 18 March 2020 in CNRS News.

Discover
cellular membrane

A nanopore to identify amino acids – Lambe

A team from the Laboratory for Analysis and Modeling in Biology and the Environment (Lambe – University of Évry/University of Cergy-Pontoise/CNRS) used a natural aerolysin nanopore to successfully identify 13 of the 20 amino acids that make up proteins.

Discover
actus

New accomplishment in gene therapies

A clinical trial for a gene therapy to treat a severe immunodeficiency has provided highly promising initial results.

Discover
View all >
With support